Tempus AI Unveils New Liquid Biopsy Assay for Early Immunotherapy Response Monitoring in Cancer

On Monday, Tempus AI Inc. (NASDAQ:TEM) announced the introduction of xM for treatment response monitoring/TRM. This new liquid biopsy assay is designed to detect molecular responses to immune-checkpoint inhibitor/ICI therapy in advanced solid tumors. Currently available for research use, xM for TRM is expected to be clinically available later in 2025.

Tempus AI Unveils New Liquid Biopsy Assay for Early Immunotherapy Response Monitoring in Cancer

A technician in a lab coat standing in a cleanroom with energy storage systems in the background.

xM for TRM is the latest addition to Tempus’ portfolio of sensitive assays for monitoring molecular response and minimal residual disease/MRD. It works by quantifying changes in circulating tumor DNA from blood samples over time, which allows for early assessment of molecular response in patients receiving ICI alone or combination therapies. The assay utilizes a multi-parametric algorithm that integrates copy number variations with somatic and germline variant allele frequencies to provide a comprehensive estimation of circulating tumor fraction.

Tempus is presenting new data on xM for TRM at the 2025 ASCO Annual Meeting. The data highlights the assay’s potential to help clinicians monitor response and refine treatment strategies, and notes that longitudinal non-molecular responders are associated with worse survival compared to molecular responders. This suggests xM for TRM can guide ICI treatment decisions. Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that provides next-gen sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic & molecular pathology testing.

While we acknowledge the potential of TEM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEM and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.